Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TCMD 
Tactile Systems Technology Inc (TCMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TCMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.83
1 Year Target Price $16.83
| 1 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 128.13% | Avg. Invested days 65 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 327.47M USD | Price to earnings Ratio 23.69 | 1Y Target Price 16.83 |
Price to earnings Ratio 23.69 | 1Y Target Price 16.83 | ||
Volume (30-day avg) 5 | Beta 1.04 | 52 Weeks Range 8.61 - 21.10 | Updated Date 10/17/2025 |
52 Weeks Range 8.61 - 21.10 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.06% | Operating Margin (TTM) 5.18% |
Management Effectiveness
Return on Assets (TTM) 4.27% | Return on Equity (TTM) 7.64% |
Valuation
Trailing PE 23.69 | Forward PE 19.12 | Enterprise Value 257610265 | Price to Sales(TTM) 1.1 |
Enterprise Value 257610265 | Price to Sales(TTM) 1.1 | ||
Enterprise Value to Revenue 0.86 | Enterprise Value to EBITDA 8.78 | Shares Outstanding 22292145 | Shares Floating 19640494 |
Shares Outstanding 22292145 | Shares Floating 19640494 | ||
Percent Insiders 2.73 | Percent Institutions 100.55 |
Upturn AI SWOT
Tactile Systems Technology Inc
Company Overview
History and Background
Tactile Systems Technology, Inc. was founded in 1993. It is focused on developing and marketing medical devices for the treatment of chronic diseases, particularly lymphedema and chronic venous insufficiency.
Core Business Areas
- Lymphedema Therapy: Develops and markets pneumatic compression devices and related garments used in the treatment of lymphedema.
- Chronic Venous Insufficiency Therapy: Offers pneumatic compression devices and garments for the treatment of chronic venous insufficiency and related conditions.
- AffloVest: The AffloVest is a mobile oscillating system designed to provide airway clearance therapy for patients with compromised airways.
Leadership and Structure
Raymond Huml is the CEO. The company has a typical corporate structure with departments such as sales, marketing, R&D, and manufacturing.
Top Products and Market Share
Key Offerings
- Flexitouch System: A pneumatic compression device used for lymphedema treatment. Market share data is difficult to pinpoint precisely, but estimates place Tactile Systems as a significant player in the pneumatic compression device market. Competitors include companies like Lympha Press and Bio Compression Systems. Revenue from this is a major part of Tactile's total revenue.
- AffloVest: A mobile airway clearance therapy device. This product addresses the niche market of patients needing airway clearance. Competitors include Hillrom (Baxter after acquisition) and Philips Respironics. Market share is lower compared to Flexitouch.
Market Dynamics
Industry Overview
The market for lymphedema and chronic venous insufficiency treatment devices is growing, driven by an aging population and increasing prevalence of these conditions. The airway clearance market is also substantial.
Positioning
Tactile Systems is positioned as a provider of advanced pneumatic compression therapy solutions, focusing on innovation and patient comfort. They are seen as a mid-sized player with a good reputation.
Total Addressable Market (TAM)
The TAM for lymphedema and venous insufficiency treatment devices is estimated in the billions of dollars. Tactile Systems is positioned to capture a portion of this TAM through its product offerings, especially Flexitouch.
Upturn SWOT Analysis
Strengths
- Strong brand reputation in the lymphedema treatment market
- Proprietary technology in pneumatic compression devices
- Established sales and distribution network
- Mobile airway clearance device AffloVest
Weaknesses
- Reliance on reimbursement policies from insurance companies
- Relatively small size compared to larger medical device companies
- High selling and marketing costs
- Dependence on a relatively small number of key products
Opportunities
- Expansion into new geographic markets
- Development of new products for related conditions
- Acquisitions of complementary technologies or businesses
- Increasing awareness of lymphedema and chronic venous insufficiency
Threats
- Changes in reimbursement policies
- Increased competition from larger medical device companies
- Product liability claims
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- BSGM
- ATRS
- HILLROM (Now Baxter)
Competitive Landscape
Tactile Systems competes with both larger and smaller medical device companies. Its competitive advantage lies in its specialized focus on lymphedema and chronic venous insufficiency and their AffloVest option, along with its established sales network and brand reputation.
Growth Trajectory and Initiatives
Historical Growth: Historically, Tactile Systems has experienced revenue growth driven by increased adoption of its Flexitouch system.
Future Projections: Analysts project continued revenue growth, driven by increasing awareness of lymphedema and expansion into new markets.
Recent Initiatives: Recent initiatives include expanding the sales force, investing in marketing programs, and developing new product features.
Summary
Tactile Systems Technology is a mid-sized player in the medical device industry, specializing in devices for lymphedema and chronic venous insufficiency treatment, and airway clearance. Their Flexitouch system is a strong product, but they face competition and reimbursement challenges. Future growth depends on expanding into new markets and developing new products. A key area of focus should be navigating reimbursement policies and continuing innovation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
- Zacks Investment Research
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data is based on publicly available information and may not be complete or accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tactile Systems Technology Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2016-07-28 | CEO, President & Director Ms. Sheri Louise Dodd | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1037 | Website https://tactilemedical.com |
Full time employees 1037 | Website https://tactilemedical.com | ||
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.